Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01621321

Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis

Allergic Bronchopulmonary Aspergillosis Clinical Trial

Official title:
A Randomized Controlled Trial of Voriconazole in Allergic Bronchopulmonary Aspergillosis

Clinical Trial Summary

This is a research project to evaluate the efficacy and safety of two different treatment protocols in Allergic bronchopulmonary Aspergillosis.

Clinical Trial Description

Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder caused by a complex hypersensitivity response to antigens released by the fungus Aspergillus fumigatus. The management of ABPA includes two important aspects - institution of immunosuppressive therapy in the form of glucocorticoids to control the immunologic activity, and close monitoring for detection of relapses. Another possible target is to use antifungal agents to attenuate the fungal burden secondary to the fungal colonization in the airways. Oral corticosteroids are currently the treatment of choice for ABPA associated with bronchial asthma.They not only suppress the immune hyperfunction but are also anti-inflammatory. However, there is no data to guide the dose and duration of glucocorticoids and different regimens of glucocorticoids have been used in literature.Itraconazole, an oral triazole with relatively low toxicity, is active against Aspergillus spp. in vitro and in vivo. The activity of itraconazole against Aspergillus spp. is more than that of ketoconazole. The administration of itraconazole can eliminate Aspergillus in the airways and can theoretically reduce the allergic responses in ABPA. The new triazoles, such as voriconazole, have recently been found effective in the treatment of fungal infections. The investigators hypothesize that voriconazole might also be useful in the treatment of ABPA. The aim of this prospective randomized controlled trial (RCT) is to evaluate the efficacy and safety of voriconazole therapy in patients with ABPA. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01621321
Study type Interventional
Source Postgraduate Institute of Medical Education and Research
Contact
Status Completed
Phase Phase 2/Phase 3
Start date June 2013
Completion date April 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT01222273 - Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis N/A
Completed NCT04442269 - Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) Phase 2
Terminated NCT00787917 - An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA) Phase 4
Completed NCT02273661 - Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded). Phase 2
Not yet recruiting NCT05129033 - A Prospective Study on Optimizing Treatment for ABPA N/A
Completed NCT02440009 - A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Completed NCT01857479 - A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Not yet recruiting NCT06244979 - iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine Phase 2
Completed NCT00585364 - Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA N/A
Recruiting NCT05444946 - Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome N/A
Terminated NCT03960606 - Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis Phase 2
Active, not recruiting NCT04227483 - Deflazacort vs. Prednisolone in Acute-stage ABPA Phase 2/Phase 3
Withdrawn NCT05903612 - Allergic Bronchopulmonary Aspergillosis Prescreening Study
Completed NCT04229303 - Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects Phase 1
Completed NCT04476758 - Immune Profiles in CF Fungal Infection
Withdrawn NCT04108962 - Benralizumab in the Treatment of Patients With Severe Asthma With ABPA Phase 4
Recruiting NCT06174922 - A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis Phase 3
Completed NCT01321827 - Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Completed NCT00974766 - Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Completed NCT03059992 - Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Phase 3